Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

NEW YORK, Aug. 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present an overview of the Company's lead drug candidates, KRX-0401 (perifosine) and Zerenex(TM), at the upcoming Rodman & Renshaw Annual Global Investment Conference in New York City. Mr. Bentsur's presentation will take place on Wednesday, September 9th at 2:50 pm ET at the New York Palace Hotel (Spellman Salon, 5th Floor) and will be audio webcast live, accessible from the Investor Information page of the Company's website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

Additionally, Keryx Biopharmaceuticals, Inc. today announced that it will host an Investor/Analyst Day on Tuesday, September 22nd in New York City beginning at 5:30 pm ET, by invitation only. Scheduled speakers include:

Discussing Perifosine Phase 3 SPA in Multiple Myeloma:

Kenneth C. Anderson, M.D.

  • Director, Jerome Lipper Multiple Myeloma Center and Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute.
  • Dr. Anderson's team at Dana-Farber Cancer Institute led clinical trials in multiple myeloma of the novel proteasome inhibitor Velcade(R), as well as the immunomodulatory drug Revlimid(R).

Discussing Perifosine Phase 2 Results in Colon Cancer:

Johanna Bendell, M.D.

  • Director, GI Oncology Research and Assoc. Director, Drug Development Unit, Sarah Cannon Research Institute.
  • Dr. Bendell has served as an invest
    '/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... organic compounds, which are mixed with animal feed to ... gain, and improve gut health and digestion. Amidst the ... eggs and meat across the globe, the need for ... aquaculture sectors is on the rise, thereby driving demand ...
(Date:9/30/2014)... of patients with bowel cancer for a genetic condition ... ovarian cancers, new research has found. , In a ... of Medicine and researchers from the University of Exeter,s ... screening programme for a genetic condition known as Lynch ... a caused by changes in genes which check the ...
(Date:9/30/2014)... research report published in the October 2014 issue of ... detection of cancer as easy as a simple blood test. ... not only detect some cancers earlier than ever before, but ... as well as identify those more likely to develop cancer ... cancer detection, so helping to save peoples, lives," said Diana ...
(Date:9/30/2014)... HealthDay Reporter , MONDAY, ... given broad-spectrum antibiotics before the age of 2 may ... childhood, new research suggests. Broad-spectrum antibiotics target a ... the study. "It is a reason to think ... are picking," said lead researcher Dr. Charles Bailey, attending ...
(Date:9/30/2014)... 2014 Visit Pam and Steve’s quiet ... you will find a loving couple facing the most ... , Steve was diagnosed with ALS – ... – just before the couple’s second wedding anniversary. ... new video, “Care, Support & ALS,” that’s ...
Breaking Medicine News(10 mins):Health News:Rising Consumption of Meat and Meat Products to Fuel Growth in the Global Feed Acidifiers Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Consumption of Meat and Meat Products to Fuel Growth in the Global Feed Acidifiers Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2
... brain development, the brains first cells neuroepithelial stem cells ... evolves into the various cells of the fully formed brain. ... critical for these stem cells to divide correctly. Without it, ... offers insight into the first steps of brain development, and ...
... QMed, Inc. (Nasdaq:,QMED) today announced financial results for ... Revenue for the year decreased to,$5,246,789 from $8,136,305 a ... $(0.66) per share on a diluted basis, compared to ... basis the previous year.,Revenue for the three-month period ended ...
... hairdressers, barbers , , WEDNESDAY, March 26 (HealthDay News) -- ... had high concentrations of coloring ingredients appear to be ... new report contends. , The authors said the findings ... -- that hair dyes appear to increase the risk ...
... Emergency Medicine is hosting the 11th annual Society of ... Mesa, Calif. As part of the forum, UC Irvine ... variety of related areas ranging from the continued decline ... computerized alcohol-use counseling. , Emergency department ...
... Aging Specialist to Consult with Award-Winning Mind Fitness ... America Conference,Booth #1317) -- CogniFit, Ltd., the company ... software that will enhance human cognitive,performance and health, ... of,Gloria Cavanaugh, long-time president of the American Society ...
... protein, study says. , , WEDNESDAY, March 26 (HealthDay News) -- Keeping ... because it,s harder for women to replace muscle that,s lost naturally ... of 29 healthy women and men, aged 65 to 80, found ... mass -- a key difference in the way women,s and men,s ...
Cached Medicine News:Health News:Key factor in brain development revealed, offers insight into disorder 2Health News:Key factor in brain development revealed, offers insight into disorder 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 2Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 4Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 5Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 6Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 7Health News:Now-Banned Hair Dyes Linked to Bladder Cancer 2Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Older Women Have Harder Time Preserving Muscle Than Men 2
(Date:9/30/2014)... Sept. 30, 2014  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) ... the post-approval study of its NeuRx DPS® System ... meet the FDA enrollment requirement was implanted over ... The NeuRx DPS®, which is the only medical ... patients, is a humanitarian device that obtained approval ...
(Date:9/30/2014)... Sept. 30, 2014  eHealth, electronic access of ... access of this information, has become a major ... that has not translated into user-friendly, effective products. ... - http://photos.prnewswire.com/prnh/20140929/149123 For ... years developing MWD® Health Manager iEHR, a multilingual ...
(Date:9/30/2014)... Sept. 30, 2014 It is evident from the ... is not performing upto expectations due to the lack of ... with the intake of omega-3 fatty acids. Among omega-3 ingredient ... fish oil, attributed to the large vegetarian population in ... polyunsaturated fatty acid (PUFAs) ingredients is in growth stage of ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... The 2009 Frost & Sullivan European Medical ... the radiology applications market is conferred on Viatronix ... the diagnostic imaging space. , (Logo: ... Viatronix has shown dedication to both developing and ...
... PAC, a leading global provider of advanced analytical instruments ... of the ANTEK MultiTek(TM) testing system for the fast, ... and halides. Industries include BioFuels, Chemicals, Food & Beverage, ... , "MultiTek(TM) is the only instrument on the ...
Cached Medicine Technology:Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 2Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 3Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 4New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: